Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome

Figure 7 Teneligliptin increased the phosphorylation of AMPK against high glucose in cardiomyocytes. Primary cardiomyocytes were treated with high glucose (30 mmol/L) with or without teneligliptin (2.5 or 5 µM) for 24 h. Levels of p-AMPK were measured by western blot assays. ^aP < 0.05 vs control group; ^bP < 0.05 vs high glucose 30 mmol/L + teneligliptin 0 µM group, n = 5.